Intelligence
Pricing

Healthcare

Protagenic Therapeutics Partners with Regulatory and Operational Experts to Advance PT00114

Author:
FAQSIR News Desk
Last Updated:
Reading Time
2 min

Protagenic Therapeutics, Inc. has announced strategic collaborations with two consulting firms to enhance its operational framework and regulatory strategy as it advances PT00114, a candidate targeted for clinical trials in stress-related neuropsychiatric disorders.

#Strategic Partnerships Established

The company has engaged Floyd Regulatory Strategic Consulting, led by Dr. Eric Floyd, as its Regulatory Affairs Advisor. Dr. Floyd, who has a distinguished background in regulatory affairs, will focus on key regulatory initiatives for PT00114, including maintaining Investigational New Drug (IND) applications, preparing for pre-Phase 2 meetings with the FDA, and planning the upcoming Phase 2 submission.

In conjunction with Floyd Regulatory Strategic Consulting, Protagenic has also partnered with Danforth Health to develop institutional-grade operational processes. This collaboration aims to streamline operations and enhance the infrastructure needed for the upcoming phases of clinical trials. Danforth Health has a proven track record, having supported over 1,800 life science companies across various operational levels.

#Background on PT00114

PT00114 is Protagenic's lead therapy, designed as a first-in-class investigational neuropeptide that targets the TCAP pathway. It aims to address significant needs in treating anxiety, PTSD, and treatment-resistant depression. The program recently reported positive safety data from its Phase 1 trials, suggesting a solid foundation for progressing to Phase 2 studies later in 2026.

#Recent Operational Milestones

Protagenic has experienced recent operational successes, including the separation from Phytanix, which alleviated over $6.3 million in liabilities and reduced costs by more than $1 million annually. Such financial adjustments put Protagenic in a favorable position as it gears up for the next stages of PT00114's development.

#Leadership Statements

President of Protagenic Therapeutics, Bill Nichols Jr., emphasized the importance of these partnerships, stating that Dr. Floyd’s extensive experience will be invaluable as the company advances its regulatory strategy. He also highlighted Danforth’s capabilities in helping Protagenic establish a robust operational framework that aligns with its strategic goals and minimizes overhead costs.

#Key Takeaways

  • Protagenic Therapeutics has secured consulting partnerships with Floyd Regulatory Strategic Consulting and Danforth Health.
  • Dr. Eric Floyd will lead regulatory strategies for PT00114, focusing on IND maintenance and Phase 2 planning.
  • PT00114 is targeted at stress-related neuropsychiatric disorders, with promising Phase 1 safety data.
  • The company has improved its financial standing by completing a separation from Phytanix.
  • These collaborations are intended to enhance operational efficiency and regulatory readiness for upcoming clinical trials.

Original source: Read original article

Frequently Asked Questions

Engaging Floyd Regulatory Strategic Consulting signifies Protagenic's commitment to a robust regulatory strategy, leveraging Dr. Eric Floyd's extensive experience in the CNS field to guide the development of PT00114 and ensure successful FDA interactions.
The partnership with Danforth Health is expected to streamline Protagenic's operational processes and infrastructure, enabling efficient alignment with strategic goals and enhancing readiness for future clinical development.
PT00114 is seen as a pivotal asset within Protagenic's pipeline, being a novel therapy targeting the TCAP pathway for stress-related neuropsychiatric disorders, with promising safety data from Phase 1 trials that sets a solid foundation for further development.
Recent milestones, including the completion of the Phytanix separation and the positive Phase 1 safety study of PT00114, have significantly strengthened Protagenic’s financial position and clinical readiness, creating momentum for its upcoming Phase 2 trials.
Dr. Floyd will be instrumental in shaping the regulatory strategy for PT00114, drawing on his extensive background to navigate complex FDA requirements and enhance the programme's chances of success as it progresses to Phase 2.
Protagenic's lean operating model, supported by strategic partnerships, allows it to focus resources effectively on key initiatives, enhancing its ability to adapt and thrive in the competitive biopharmaceutical landscape.
Investors can anticipate the initiation of Phase 2 studies for PT00114 in 2026, backed by a clean capital structure and experienced advisory partners, suggesting a proactive approach to advancing the company's therapeutic offerings.
The unique mechanism of action of PT00114 targeting the TCAP pathway distinguishes it in the market and aligns with significant unmet needs in treating anxiety and depression, highlighting its potential as a breakthrough therapy.